Global Implantable Cardiac Pacemaker Treatment Market - 2023-2030

Global Implantable Cardiac Pacemaker Treatment Market - 2023-2030

Market Overview

Implantable Cardiac Pacemaker Treatment Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 4% during the forecast period (2022-2029).

In the heart, the pacemaker is a small electronic device implanted in the chest slightly below the collarbone to regulate slow electrical problems with the heart. A pacemaker is inserted to produce a faster heart rate when the heart is beating too slowly, causing problems that cannot otherwise be corrected.

Market Dynamics

The global implantable cardiac pacemaker treatment market is driven by the rise in funding from private and government agencies, the growing adoption of implantable cardiac pacemaker treatment in cardiac surgical procedures, improving patient awareness of heart surgery treatment, and the rising geriatric population.

Increasing product launches by key players drive market growth

The technological advancements and launching of new products by market players drive the market in the forecast period. Aortic valve replacement (AVR) is related to radically improved prognosis among patients with severe aortic valve disease. However, surgical and transcatheter AVR brings risks of perioperative impairment to the conduction system, requiring permanent pacemaker implantation drives the market.

The market players are applying the market strategies such as product launches and acquisitions to expand their business. For instance, in March 2022, ZOLL Medical Corporation launched the ZOLL Arrhythmia Management System (AMS). ZOLL AMS adds biometric data (heart rate, activity, respiratory rate, and body posture) to the ECG information provided by traditional MCT devices. A new study shows that ZOLL AMS helps physicians make more informed patient treatment plans. Also, in January 2022, MicroPort CRM received PMDA Japanese regulation agency acceptance for its latest scope of implantable pacemakers, Alizea. The devices are provided with Bluetooth technology for streamlined remote monitoring when paired with microPort CRM’s smart view connect home monitor, which has already been approved in Japan.

Furthermore, research and development drive the market worldwide. For instance, in June 2021, Researchers at Northwestern and George Washington universities (GW) developed the first-ever temporary pacemaker — battery-free, a wireless, fully implantable pacing device that vanishes after it’s no longer needed. The thin, lightweight, flexible device is used in patients who require quick pacing after heart surgery or while waiting for an enduring pacemaker. All elements of the pacemaker are biocompatible and naturally absorb into the body’s biofluids for five to seven weeks without needing surgical extraction.

Product recalls will hamper the growth of the market

However, risk factors related to earlier pacemaker implantation include preoperative bundle branch block, older age, and a high burden of comorbidities. In addition, product recalls is limiting the market growth. For instance, In March 2021, FDA recalled thousands of pacemakers sold by Abbott over the past four years. The electrical shorts that triggered the recall caused the devices to stop the heart pacing, report inaccurate information to doctors or drain the battery faster than predicted. This was due to the risk of electrical shorts that can result from moisture getting inside the devices.

COVID-19 Impact Analysis

The appearance of the COVID-19 pandemic considerably impacted the global implantable cardiac pacemaker treatment market. As per the article published in Cardiac Electrophysiology Clinics in 2021, COVID-19 has caused a global impact on public health services that led to the reorganization of hospital settings, including in-office visits for patients with the cardiac implantable electronic device (CIED). Remote monitoring (RM) of CIED patients represents an appropriate strategy to minimize any potential risk of virus exposure for patients and healthcare providers without compromising the quality of care. RM offers access to the same information as an in-office visit and may contribute to the early detection of atrial and ventricular arrhythmias, prevent heart failure decompensation, and manage device-related issues. Moreover, since the onset of the COVID-19 pandemic, physicians have suspended nonurgent scheduled visits and rapidly transitioned to virtual visits. Due to technological improvement, patients utilizing wearable sensors for measuring hemodynamic parameters (blood pressure and saturation, heart rate) and adopting virtual health platforms may be monitored directly from residence without any risk of infection.

Segment Analysis

The dual chamber pacemaker segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The dual-chamber pacemaker segment accounts for the largest market share. A dual-chamber pacemaker carries electrical impulses to the right ventricle and the right atrium in the heart to help control the timing of contractions between the two chambers. Dual-chamber pacemakers are suggested for treating symptomatic bradycardia due to sick sinus syndrome without an atrioventricular block. This dual-chamber pacemaker allows the two chambers to work together, contracting and relaxing in the proper rhythm. The contractions permit blood to flow properly from the right atrium into the right ventricle.

A dual-chamber pacemaker may be selected for many different reasons. For some people, the SA node’s signals are too slow, and the electrical pathway to the ventricles is partly or completely blocked. A dual-chamber pacemaker can help treat both problems. For other people, the timing of the atrial and ventricular contractions is uncoordinated (asynchronous). A dual-chamber pacemaker can restore a normal timing sequence (also called AV synchrony).

The market players are offering dual-chamber pacemaker devices in the market. For instance, Medtronic provides the Advisa MRI SureScan pacemaker, the second-generation FDA-approved pacing system developed for safe use in the MRI environment when specific conditions are met. Advisa is available in single and dual-chamber options.

Geographical Analysis

North America region holds the largest market share of the global implantable cardiac pacemaker treatment market

North America dominates the implantable cardiac pacemaker treatment market and is anticipated to show a parallel trend over the forecast period. The market is boosted by factors such as advanced healthcare infrastructure, a rise in the incidence of cardiovascular conditions, the adoption of advanced healthcare technology and rising regional research and development activities.

According to the Centers for Disease Control and Prevention, heart disease is the main cause of death for men, women, and people of most ethnic and racial categories in the United States. About 20.1 million adults aged 20 and older have CAD (about 7.2%). And in 2020, about 2 in 10 deaths from CAD happened in adults less than 65 years old.

In addition, as per the article published in Biomaterials Science, in 2020, over a million patients in the United States presently have pacemakers, and around 250,000 new permanent pacemakers are implanted every year; pacemaker placement, revision or removal is a generally performed process. Most heart pacemakers are implanted in patients over 60, but they are also employed in children, including infants, when required. The most typical indications for permanent cardiac pacing are various conduction blocks. Increasing demand for cardiac pacemakers drives the market in the North American region.

Competitive Landscape

The implantable cardiac pacemaker treatment market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Biotronik Inc., Medtronic Plc., Boston Scientific, Abbot Laboratories, Shree Pacetronix Ltd, Vitatron Holding B.V., Medico S.p.A., MicroPort Scientific Corporation, Lepu Medical Technology Co. Ltd., and Cardioelectronica, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the implantable cardiac pacemaker treatment market globally.

For instance,
• In October 2020, Medtronic launched its Azure pacemakers integrated with BlueSync technology in India. This product was intended to diagnose and minimize the risk of atrial fibrillation precisely.

BIOTRONIK Inc.

Overview:

BIOTRONIK is a privately owned medical device firm with products and services that save and enhance the lives of patients suffering from cardiovascular and endovascular diseases. Patient well-being has been their top priority for more than 50 years.

Product Portfolio:

Edora 8 DR-T/SR-T: This is small, enduring, complete, and smart. It combined small size with a whole suite of tools for complete diagnostics, powerful bradycardia therapy and eased handling— yielding long-lasting wireless devices that support efficient MRI access, timesaving remote monitoring and unique physiological rate adaptation.

The global implantable cardiac pacemaker treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.